ArticleFrontiers in medicine2025
Association between systemic inflammation response index and atrial fibrillation in chronic obstructive pulmonary disease: a multicenter cross-sectional study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Shared molecular signatures between atrial fibrillation and chronic obstructive pulmonary disease: an integrated bioinformatic analysis with experimental validation.BMC medical genomics · 2026Article
- Association and impact of inflammatory markers and cardiac structure on atrial fibrillation risk: a study integrating NHANES with real-world data.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic inflammation plays a critical role in the pathogenesis of both chronic obstructive pulmonary disease (COPD) and atrial fibrillation (AF). As an emerging biomarker reflecting systemic inflammatory status, the association between the systemic inflammation response index (SIRI) and the risk of AF in patients with COPD remains unclear. Therefore, this study aimed to investigate the association between SIRI levels and the risk of AF in patients with COPD. Methods: In this multicenter cross-sectional study, we enrolled 1,133 hospitalized COPD patients from May 2021 to May 2024 at the First Affiliated Hospital of Wenzhou Medical University and Quzhou People's Hospital. Patients were categorized into four groups based on SIRI quartiles. We used multivariate logistic regression, restricted cubic spline (RCS) analysis, and receiver operating characteristic (ROC) curves to evaluate the association between SIRI and AF risk. Subgroup, interaction, and sensitivity analyses were conducted to assess robustness and effect modification. Results: Among the study population, 225 patients (19.85%) had AF. After full adjustment, this cross-sectional analysis demonstrates that each 1-unit increase in SIRI was associated with a 4.6% higher AF risk (OR = 1.046, 95% CI: 1.018-1.075, Conclusion: Elevated SIRI levels are independently associated with an increased risk of AF in patients with COPD, especially among smokers. As a simple and readily accessible biomarker of low-grade systemic inflammation, SIRI may serve as an effective tool for assessing the risk of atrial fibrillation in patients with COPD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.